. . . . "withdrawn"@en . . . "Total clearance: 109 ml/min."@en . . . . "4.4 hours."@en . "Brotizolam is indicated for the short-term treatment (2-4 weeks) of severe or debilitating insomnia. "@en . "approved"@en . . . . . "Brotizolam synthesis: Weber, K. H.; Bauer, A.; Danneberg, P.; Kuhn, F. J.; 1978, U.S. Patent 4,094,984."@en . . . "Brotizolam"@en . . . . "Brotizolamum"@en . . "# Jochemsen R, Wesselman JG, van Boxtel CJ, Hermans J, Breimer DD: Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. Br J Clin Pharmacol. 1983;16 Suppl 2:291S-297S. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/6140948"@en . . "Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It possesses anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to short-acting benzodiazepines such as triazolam. It is used in the short term treatment of severe or debilitating insomnia. Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). Brotizolam is not approved for sale in the UK, United States or Canada. It is approved for sale in the Netherlands, Germany, Spain, Belgium, Austria, Portugal, Israel, Italy and Japan."@en . . . . . . "57801-81-7"@en . . . "The plasma concentration profile of brotizolam can be described as a one compartmental open model with first-order absorption."@en . "Brotizolam"@en . . "The mean value of the free fraction (%): 8.4 \u00B1 0.7."@en . . . . . "0.63 l/kg."@en . . . . .